Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Celularity Closes SPAC Merger With GX Acquisition, Trading Starts Monday

Author: Vandana Singh | July 16, 2021 11:27am

  • Celularity Inc has closed the merger with GX Acquisition Corp (NASDAQ:GXGX), giving Celularity $138 million to push the NK cell and T cell therapies into early-stage trials.
  • The combined company will operate under the name Celularity Inc (NASDAQ:CELU), and its common stock will commence trading on the NASDAQ from Monday (19 July) under the ticker symbol CELU.
  • The company expanded its ongoing Phase 1 trial of CYNK-001 in patients with acute myeloid leukemia (AML)to include patients with relapsed/refractory AML (r/r AML) in addition to its ongoing trial in measurable residual disease (MRD).
  • To date, no dose-limiting toxicity was observed with outpatient administration of three doses. 
  • The FDA granted Orphan Drug Designation to CYNK-001 for the treatment of patients with malignant gliomas. 
  • CYNK-001 is currently in a Phase 1 trial for glioblastoma multiforme.
  • For Phase 1/2 COVID-19 trial assessing CYNK-001, no evidence of dose-limiting toxicities or evidence of no worsening inflammatory biomarkers was observed, and enrollment is ongoing.
  • Price Action: GXGX shares are up 32.20% at $10.60 during the market session on the last check Friday.

Posted In: CELU FPX GXGX IPO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist